We found that lower counts (/μL) of T lymphocyte subsets CD8+T cells (<201) were associated with a higher risk of composite outcome, and lower counts (/μL) of CD4+T cells (<368) and CD8+T cells (<201) were significantly associated with the death outcome of COVID‐19 patients with Nirmatrelvir therapy. This evidence concerns the gene CD8A and COVID-19.